Avoro Capital Advisors ARGX Position
Active12-Fund ConvergenceAvoro Capital Advisors held their position in argenx SE (ARGX) in Q4 2025, holding $832.5M worth of shares across 990,000 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
ARGX is a convergence signal: 12 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Efgartigimod in 106 days (Jul 31, 2026), making the timing of Avoro Capital's position particularly relevant.
About argenx SE
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Full company profile →Short Interest
3.4%
5.1 days to cover
Avoro Capital Advisors ARGX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 990,000 | — | $832.5M |
| Q3 2025 | Decreased | 990,000 | -185,000 | $730.2M |
| Q2 2025 | Decreased | 1,175,000 | -60,177 | $647.7M |
| Q1 2025 | Decreased | 1,235,177 | -3,290 | $731.1M |
| Q4 2024 | Held | 1,238,467 | — | $761.7M |
| Q3 2024 | Held | 1,238,467 | — | $671.3M |
| Q2 2024 | Held | 1,238,467 | — | $532.6M |
| Q1 2024 | Increased | 1,238,467 | +3,900 | $487.6M |
| Q4 2023 | Increased | 1,234,567 | +234,567 | $469.7M |
| Q3 2023 | Decreased | 1,000,000 | -263,500 | $491.6M |
| Q2 2023 | Decreased | 1,263,500 | -24,000 | $492.4M |
| Q1 2023 | New | 1,287,500 | +1,287,500 | $479.7M |
Frequently Asked Questions
Does Avoro Capital Advisors own ARGX?
Yes. As of Q4 2025, Avoro Capital Advisors holds 990,000 shares of argenx SE (ARGX) valued at $832.5M. This data comes from their SEC 13F filing.
How many hedge funds own ARGX?
12 specialist biotech hedge funds currently hold ARGX, including RTW Investments, Deep Track Capital, Eventide Asset Management and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy ARGX?
Avoro Capital Advisors's position in ARGX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's ARGX position increasing or decreasing?
Avoro Capital Advisors held their ARGX position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ARGXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →